chaetoglobosin B | 50335-04-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: chaetoglobosin B
• 英文别名: (1R,3E,6R,7E,9S,11E,13R,14S,17R,18S)-6,14-dihydroxy-18-(1H-indol-3-ylmethyl)-7,9,15,16-tetramethyl-19-azatricyclo[11.7.0.01,17]icosa-3,7,11,15-tetraene-2,5,20-trione
• CAS: 50335-04-1
• 化学式: C₃₂H₃₆N₂O₅
• 分子量: 528.648
• InChiKey: VUEFRYQBOMQOMV-MLXGBZTESA-N

物化性质

• 沸点：
  822.4±65.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  39
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  chaetoglobosin B 在 三乙胺 作用下， 以 吡啶 为溶剂， 生成 chaetoglobosin G monoacetate
  参考文献：
  名称：

  Chaetoglobosins, cytotoxic 10-(indol-3-yl)-(13)cytochalasans from Chaetomium spp. III. Structures of chaetoglobosins C, E, F, G, and J.

  摘要：

  根据物理数据，特别是1H-NMR和化学相关性，确定了chaetoglobosins C、E、F、G和J（10-(吲哚-3-基)-[13]细胞色素）的结构（图1）。本文讨论了chaetoglobosins的立体结构特征。

  DOI：

  10.1248/cpb.30.1629
• 作为产物：
  描述：

  毛壳球菌素 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以3 mg的产率得到chaetoglobosin B
  参考文献：
  名称：

  Chaetoglobosins, cytotoxic 10-(indo-3-yl)-(13)cytochalasans from Chaetomium spp. II. Structures of chaetoglobosins A, B, and D.

  摘要：

  通过异构化反应和物理方法（包括精确的 1H-NMR 解偶联实验），阐明了 10-（吲哚-3-基）-[13] 环荼蘼素（Chaetoglobosins A、B 和 D）的结构（图 7）。

  DOI：

  10.1248/cpb.30.1618

文献信息

• Chaetoglobosin O and Other Phytotoxic Metabolites from<i>Cylindrocladium floridanum</i>, a Causal Fungus of Alfalfa Black Rot Disease
  作者：Akitami Ichihara、Kinya Katayama、Hiroshi Teshima、Hideaki Oikawa、Sadao Sakamura

  DOI：10.1271/bbb.60.360

  日期：1996.1

  Several phytotoxic metabolites, including a novel compound chaetoglobosin O, were isolated from Cylindrocladium floridanum Sobers et Seymore. The structure of chaetoglobosin O, including its absolute configuration, was determined by a spectroscopic analysis and chemical correlation. Purified chaetoglobosins A, C, and O showed potent growth-inhibition activity against alfalfa seedlings.

  从圆筒孢属真菌（Cylindrocladium floridanum Sobers et Seymore）中分离出多种植物毒性代谢产物，包括一种新型化合物chaetoglobosin O。通过光谱分析和化学相关性确定了chaetoglobosin O的结构，包括其绝对构型。纯化的chaetoglobosins A、C和O对紫花苜蓿幼苗显示出强大的生长抑制活性。
• Intravascular stent with cytoskeletal inhibitors for the prevention of restenosis
  申请人：Boston Scientific Limited

  公开号：EP1512398A1

  公开（公告）日：2005-03-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Use of cytoskeletal inhibitors in crystalline form for the inhibition or prevention of restenosis
  申请人：BOSTON SCIENTIFIC SCIMED LIMITED

  公开号：EP2098230A1

  公开（公告）日：2009-09-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Therapeutic inhibitors of vascular smooth muscle cells
  申请人：Boston Scientific Limited

  公开号：EP2298310A2

  公开（公告）日：2011-03-23

  Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

  本发明提供了抑制哺乳动物宿主血管创伤或疾病后狭窄的方法，包括向宿主施用治疗有效剂量的治疗共轭物，该共轭物含有血管平滑肌结合蛋白，该蛋白以特定方式与血管平滑肌细胞的细胞表面结合，并与抑制肌肉细胞的细胞活性的治疗剂剂型耦合。还提供了向血管平滑肌细胞直接和/或靶向输送治疗剂的方法，这种方法通过抑制平滑肌细胞收缩，使血管腔扩张和固定，从而构成生物支架。
• Dosage form comprising taxol in crystalline form
  申请人：BOSTON SCIENTIFIC SCIMED LIMITED

  公开号：EP2292225A1

  公开（公告）日：2011-03-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。